(Q24243499)

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Effects on immunological and virological outcome of patients using one protease inhibitor or one non-nucleoside reverse transcriptase inhibitor in a triple antiretroviral therapy: normal clinical practice versus clinical trial findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Comparison of a rule-based algorithm with a phenotype-based algorithm for the interpretation of HIV genotypes in guiding salvage regimens in HIV-infected patients by a randomized clinical trial: the mutations and salvage study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Efficacy and safety of a once-daily fixed-dose combination of abacavir/lamivudine compared with abacavir twice daily and lamivudine once daily as separate entities in antiretroviral-experienced HIV-1-infected patients (CAL30001 Study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Comparison of four-drug regimens and pairs of sequential three-drug regimens as initial therapy for HIV-1 infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Clinical utility of HIV-1 genotyping and expert advice: the Havana trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Antiretroviral therapy adherence and viral suppression in HIV-infected drug users: comparison of self-report and electronic monitoring

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Persistence and fitness of multidrug-resistant human immunodeficiency virus type 1 acquired in primary infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Adverse effects of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Severe hepatic failure related to nevirapine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Efavirenz use during pregnancy and for women of child-bearing potential

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Initial highly-active antiretroviral therapy with a protease inhibitor versus a non-nucleoside reverse transcriptase inhibitor: discrepancies between direct and indirect meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Time trends in primary HIV-1 drug resistance among recently infected persons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Clinical uses of non-nucleoside reverse transcriptase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Evaluation of an efavirenz-containing regimen: an open-label, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 recommendations of an International AIDS Society-USA Panel

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Causes of the decline in AIDS deaths, United States, 1995-2002: prevention, treatment or both?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Use of changes in plasma levels of human immunodeficiency virus type 1 RNA to assess the clinical benefit of antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Prognosis in HIV-1 infection predicted by the quantity of virus in plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Clinical manifestations and management of antiretroviral nucleoside analog-related mitochondrial toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Efavirenz-induced skin eruption and successful desensitization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Detection of drug resistance associated mutations in HIV primary infection within the UK.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Clinical, virologic, and immunologic response to efavirenz-or protease inhibitor-based highly active antiretroviral therapy in a cohort of antiretroviral-naive patients with advanced HIV infection (EfaVIP 2 study).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Understanding and avoiding antiretroviral adverse events

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

South Africa to tighten control on drug trials after five death

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

[Efavirenz (Sustiva) in pregnancy: a study about 12 HIV patients]

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

7 January 2021

ACTG (AIDS Clinical Trials Group) 384: a strategy trial comparing consecutive treatments for HIV-1

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

7 January 2021

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

7 January 2021

Drug resistance after failure of initial antiretroviral therapy in resource-limited countries

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

7 January 2021

Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

7 January 2021

Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

7 January 2021

National adult antiretroviral therapy guidelines in resource-limited countries: concordance with 2003 WHO guidelines?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

7 January 2021

Patients' groups to sue tobacco industry in Spain

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD006517.PUB2

7 January 2021